A little more than four years after striking its first deal with Aduro Biotech Inc., Johnson & Johnson's Janssen Biotech Inc. is terminating research and licensing agreements for the Berkeley, Calif.-based company's experimental lung and prostate cancer treatments. The termination leaves about $1.1 billion in potential milestone payments to Aduro unrealized, and returns three programs based on its live, attenuated double-deleted Listeria (LADD) technology platform to the company. (See BioWorld Today, Oct. 17, 2014.)